Share Price and Basic Stock Data
Last Updated: November 8, 2024, 12:47 pm
PEG Ratio | 1.88 |
---|
Competitors of Sun Pharmaceuticals Industries Ltd
Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
---|---|---|---|---|---|---|---|---|---|
Gujarat Themis Biosyn Ltd | 3,565 Cr. | 327 | 390/108 | 67.6 | 20.5 | 0.20 % | 45.0 % | 33.8 % | 1.00 |
Gujarat Terce Laboratories Ltd | 61.1 Cr. | 82.3 | 94.9/22.7 | 23.4 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
Gujarat Inject (Kerala) Ltd | 25.8 Cr. | 17.6 | 19.5/7.60 | 33.6 | 6.64 | 0.00 % | 4.06 % | 3.33 % | 10.0 |
Godavari Drugs Ltd | 91.8 Cr. | 122 | 155/87.0 | 14.2 | 51.8 | 0.00 % | 12.7 % | 15.5 % | 10.0 |
Glenmark Life Sciences Ltd | 13,356 Cr. | 1,090 | 1,335/620 | 31.5 | 207 | 2.03 % | 28.1 % | 21.1 % | 2.00 |
Industry Average | 19,951.73 Cr | 1,273.83 | 61.80 | 190.23 | 0.31% | 16.78% | 15.93% | 6.64 |
Quarterly Result
Month | Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 8,523 | 9,719 | 9,626 | 9,863 | 9,447 | 10,762 | 10,952 | 11,241 | 10,931 | 11,941 | 12,192 | 12,381 | 11,983 |
Expenses | 6,475 | 6,898 | 6,996 | 7,257 | 7,106 | 7,877 | 7,996 | 8,237 | 8,129 | 8,609 | 9,013 | 8,904 | 8,948 |
Operating Profit | 2,048 | 2,821 | 2,630 | 2,606 | 2,340 | 2,884 | 2,957 | 3,004 | 2,802 | 3,332 | 3,179 | 3,477 | 3,035 |
OPM % | 24% | 29% | 27% | 26% | 25% | 27% | 27% | 27% | 26% | 28% | 26% | 28% | 25% |
Other Income | -562 | -479 | 223 | 433 | -3,822 | 2 | 85 | 174 | 202 | -118 | 294 | 180 | 504 |
Interest | 30 | 35 | 36 | 19 | 37 | 14 | 19 | 46 | 93 | 81 | 49 | 35 | 74 |
Depreciation | 553 | 503 | 530 | 554 | 556 | 588 | 610 | 660 | 672 | 651 | 633 | 622 | 650 |
Profit before tax | 903 | 1,804 | 2,287 | 2,466 | -2,076 | 2,285 | 2,412 | 2,471 | 2,240 | 2,481 | 2,791 | 3,000 | 2,816 |
Tax % | 6% | 22% | 9% | 14% | -7% | 8% | 6% | 11% | 10% | 19% | 14% | 14% | 5% |
Net Profit | 842 | 1,404 | 2,086 | 2,126 | -2,227 | 2,093 | 2,256 | 2,181 | 1,983 | 2,006 | 2,385 | 2,561 | 2,659 |
EPS in Rs | 3.73 | 6.02 | 8.53 | 8.58 | -9.49 | 8.59 | 9.43 | 9.03 | 8.27 | 8.43 | 9.90 | 10.52 | 11.06 |
Last Updated: Unknown
Profit & Loss - Annual Report
Last Updated: Unknown
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales | 11,131 | 16,080 | 27,392 | 28,487 | 31,578 | 26,489 | 29,066 | 32,838 | 33,498 | 38,654 | 43,886 | 48,497 |
Expenses | 6,346 | 9,078 | 19,498 | 20,313 | 21,476 | 20,858 | 22,689 | 25,855 | 25,028 | 28,397 | 32,235 | 35,479 |
Operating Profit | 4,784 | 7,003 | 7,894 | 8,174 | 10,102 | 5,631 | 6,377 | 6,983 | 8,470 | 10,258 | 11,650 | 13,018 |
OPM % | 43% | 44% | 29% | 29% | 32% | 21% | 22% | 21% | 25% | 27% | 27% | 27% |
Other Income | -90 | -1,968 | 283 | -42 | 610 | -135 | -258 | 382 | -3,449 | -3,505 | 459 | 865 |
Interest | 43 | 44 | 579 | 523 | 400 | 518 | 555 | 303 | 141 | 127 | 172 | 238 |
Depreciation | 336 | 409 | 1,195 | 1,038 | 1,265 | 1,500 | 1,753 | 2,053 | 2,080 | 2,144 | 2,529 | 2,557 |
Profit before tax | 4,315 | 4,581 | 6,403 | 6,571 | 9,048 | 3,479 | 3,810 | 5,010 | 2,799 | 4,481 | 9,408 | 11,088 |
Tax % | 20% | 15% | 14% | 14% | 13% | 26% | 16% | 16% | 18% | 24% | 9% | 13% |
Net Profit | 3,469 | 3,879 | 5,476 | 5,658 | 7,846 | 2,542 | 3,208 | 4,172 | 2,272 | 3,389 | 8,513 | 9,610 |
EPS in Rs | 14.40 | 15.17 | 21.92 | 18.89 | 29.03 | 8.73 | 11.11 | 15.69 | 12.10 | 13.64 | 35.32 | 39.91 |
Dividend Payout % | 9% | 10% | 14% | 5% | 12% | 23% | 25% | 25% | 62% | 73% | 33% | 34% |
YoY Net Profit Growth
Year | 2013-2014 | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 |
---|---|---|---|---|---|---|---|---|---|---|---|
YoY Net Profit Growth (%) | 11.82% | 41.17% | 3.32% | 38.67% | -67.60% | 26.20% | 30.05% | -45.54% | 49.16% | 151.20% | 12.89% |
Change in YoY Net Profit Growth (%) | 0.00% | 29.35% | -37.85% | 35.35% | -106.27% | 93.80% | 3.85% | -75.59% | 94.71% | 102.03% | -138.31% |
Sun Pharmaceuticals Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.
Growth
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 11% |
3 Years: | 13% |
TTM: | 9% |
Compounded Profit Growth | |
---|---|
10 Years: | 8% |
5 Years: | 23% |
3 Years: | 25% |
TTM: | 25% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 34% |
3 Years: | 31% |
1 Year: | 54% |
Return on Equity | |
---|---|
10 Years: | 14% |
5 Years: | 14% |
3 Years: | 16% |
Last Year: | 17% |
Last Updated: Unknown
Balance Sheet
Last Updated: Unknown
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 104 | 207 | 207 | 241 | 240 | 240 | 240 | 240 | 240 | 240 | 240 | 240 |
Reserves | 14,886 | 18,318 | 25,431 | 32,742 | 36,400 | 38,074 | 41,169 | 45,025 | 46,223 | 47,771 | 55,755 | 63,427 |
Borrowings | 260 | 2,561 | 8,996 | 8,497 | 9,832 | 10,385 | 10,514 | 8,315 | 3,869 | 1,290 | 6,886 | 3,274 |
Other Liabilities | 5,128 | 8,009 | 14,089 | 13,948 | 14,624 | 15,598 | 12,666 | 14,615 | 17,291 | 20,474 | 17,831 | 18,367 |
Total Liabilities | 20,377 | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,308 |
Fixed Assets | 5,647 | 6,817 | 12,682 | 15,872 | 17,675 | 18,853 | 21,837 | 22,847 | 21,553 | 22,665 | 24,065 | 23,211 |
CWIP | 563 | 842 | 2,039 | 2,175 | 2,801 | 2,465 | 1,411 | 1,220 | 1,567 | 1,287 | 4,973 | 5,354 |
Investments | 2,412 | 2,786 | 2,716 | 1,830 | 1,192 | 7,143 | 7,903 | 10,143 | 9,612 | 12,849 | 14,824 | 15,026 |
Other Assets | 11,756 | 18,650 | 31,286 | 35,550 | 39,427 | 35,837 | 33,439 | 33,984 | 34,890 | 32,975 | 36,849 | 41,717 |
Total Assets | 20,377 | 29,095 | 48,723 | 55,428 | 61,095 | 64,297 | 64,590 | 68,194 | 67,622 | 69,776 | 80,712 | 85,308 |
Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | -256.00 | 5.00 | -1.00 | 0.00 | 1.00 | -5.00 | -4.00 | -2.00 | 5.00 | 9.00 | 5.00 | 10.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
Month | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 79 | 50 | 68 | 87 | 83 | 108 | 112 | 105 | 99 | 99 | 95 | 85 |
Inventory Days | 454 | 410 | 307 | 370 | 307 | 338 | 366 | 311 | 378 | 315 | 360 | 338 |
Days Payable | 186 | 174 | 178 | 207 | 197 | 234 | 192 | 142 | 167 | 158 | 194 | 194 |
Cash Conversion Cycle | 347 | 286 | 197 | 251 | 193 | 212 | 285 | 274 | 310 | 255 | 261 | 229 |
Working Capital Days | 111 | 126 | 76 | 104 | 73 | 79 | 137 | 112 | 84 | 55 | 93 | 78 |
ROCE % | 32% | 34% | 23% | 18% | 20% | 10% | 10% | 10% | 13% | 17% | 16% | 17% |
Mutual Fund Holdings
Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
---|---|---|---|---|---|---|
SBI Nifty 50 ETF | 19,868,445 | 1.43 | 2502.33 | 6,950,290 | 2024-11-06 | 185.86% |
ICICI Prudential Value Discovery Fund | 18,245,002 | 6.12 | 2297.87 | 6,950,290 | 2024-11-06 | 162.51% |
SBI S&P BSE Sensex ETF | 14,074,237 | 1.65 | 1773.35 | 6,950,290 | 2024-11-06 | 102.5% |
ICICI Prudential Equity & Debt Fund | 7,973,496 | 3.37 | 1004.22 | 6,950,290 | 2024-11-06 | 14.72% |
ICICI Prudential Bluechip Fund | 7,743,881 | 2.03 | 975.3 | 6,950,290 | 2024-11-06 | 11.42% |
Axis Bluechip Fund | 6,950,290 | 2.64 | 875.35 | 6,950,290 | 2024-11-06 | 0% |
HDFC Balanced Advantage Fund - Regular Plan | 6,700,612 | 1.15 | 843.91 | 6,950,290 | 2024-11-06 | -3.59% |
Nippon India Pharma Fund | 6,556,349 | 12.76 | 825.74 | 6,950,290 | 2024-11-06 | -5.67% |
Aditya Birla Sun Life Flexi Cap Fund | 6,516,359 | 4.24 | 820.7 | 6,950,290 | 2024-11-06 | -6.24% |
HDFC Top 100 Fund - Regular Plan | 6,434,009 | 2.68 | 810.33 | 6,950,290 | 2024-11-06 | -7.43% |
Key Financial Ratios
Month | Mar 24 | Mar 23 | Mar 22 | Mar 21 | Mar 20 |
---|---|---|---|---|---|
FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Basic EPS (Rs.) | 39.90 | 35.30 | 13.60 | 12.10 | 15.70 |
Diluted EPS (Rs.) | 39.90 | 35.30 | 13.60 | 12.10 | 15.70 |
Cash EPS (Rs.) | 50.87 | 46.22 | 23.13 | 18.19 | 26.01 |
Book Value[Excl.RevalReserv]/Share (Rs.) | 279.69 | 247.22 | 212.84 | 206.23 | 204.75 |
Book Value[Incl.RevalReserv]/Share (Rs.) | 279.69 | 247.22 | 212.84 | 206.23 | 204.75 |
Revenue From Operations / Share (Rs.) | 202.13 | 182.91 | 161.11 | 139.62 | 136.86 |
PBDIT / Share (Rs.) | 59.92 | 51.19 | 47.18 | 38.87 | 31.78 |
PBIT / Share (Rs.) | 49.27 | 40.64 | 38.24 | 30.20 | 23.23 |
PBT / Share (Rs.) | 46.21 | 39.21 | 18.68 | 11.67 | 20.88 |
Net Profit / Share (Rs.) | 40.21 | 35.68 | 14.20 | 9.52 | 17.45 |
NP After MI And SOA / Share (Rs.) | 39.91 | 35.32 | 13.64 | 12.10 | 15.69 |
PBDIT Margin (%) | 29.64 | 27.98 | 29.28 | 27.84 | 23.22 |
PBIT Margin (%) | 24.37 | 22.22 | 23.73 | 21.63 | 16.97 |
PBT Margin (%) | 22.86 | 21.43 | 11.59 | 8.35 | 15.25 |
Net Profit Margin (%) | 19.89 | 19.50 | 8.81 | 6.82 | 12.75 |
NP After MI And SOA Margin (%) | 19.74 | 19.30 | 8.46 | 8.66 | 11.46 |
Return on Networth / Equity (%) | 15.04 | 15.13 | 6.81 | 6.24 | 8.31 |
Return on Capital Employeed (%) | 17.26 | 16.02 | 17.44 | 14.06 | 10.60 |
Return On Assets (%) | 11.20 | 10.49 | 4.68 | 4.29 | 5.51 |
Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 |
Total Debt / Equity (X) | 0.04 | 0.11 | 0.01 | 0.07 | 0.16 |
Asset Turnover Ratio (%) | 0.58 | 0.58 | 0.56 | 0.49 | 0.49 |
Current Ratio (X) | 2.56 | 2.00 | 2.04 | 1.89 | 2.02 |
Quick Ratio (X) | 1.98 | 1.48 | 1.51 | 1.33 | 1.51 |
Inventory Turnover Ratio (X) | 0.67 | 0.79 | 0.78 | 0.72 | 0.69 |
Dividend Payout Ratio (NP) (%) | 30.26 | 29.73 | 65.96 | 53.68 | 36.62 |
Dividend Payout Ratio (CP) (%) | 23.88 | 22.89 | 39.85 | 31.28 | 23.70 |
Earning Retention Ratio (%) | 69.74 | 70.27 | 34.04 | 46.32 | 63.38 |
Cash Earning Retention Ratio (%) | 76.12 | 77.11 | 60.15 | 68.72 | 76.30 |
Interest Coverage Ratio (X) | 60.29 | 71.40 | 88.88 | 65.95 | 25.19 |
Interest Coverage Ratio (Post Tax) (X) | 43.53 | 51.77 | 63.60 | 47.60 | 15.69 |
Enterprise Value (Cr.) | 384570.80 | 239622.86 | 218440.19 | 143296.74 | 89454.34 |
EV / Net Operating Revenue (X) | 7.93 | 5.46 | 5.65 | 4.28 | 2.72 |
EV / EBITDA (X) | 26.75 | 19.51 | 19.30 | 15.36 | 11.73 |
MarketCap / Net Operating Revenue (X) | 8.02 | 5.37 | 5.68 | 4.28 | 2.57 |
Retention Ratios (%) | 69.73 | 70.26 | 34.03 | 46.31 | 63.37 |
Price / BV (X) | 6.11 | 4.21 | 4.57 | 3.09 | 1.87 |
Price / Net Operating Revenue (X) | 8.02 | 5.37 | 5.68 | 4.28 | 2.57 |
EarningsYield | 0.02 | 0.03 | 0.01 | 0.02 | 0.04 |
Strength and Weakness
Strength | Weakness |
---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Sun Pharmaceuticals Industries Ltd:
- Net Profit Margin: 19.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 17.26% (Industry Average ROCE: 16.62%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 15.04% (Industry Average ROE: 15.49%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 43.53
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.98
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.6 (Industry average Stock P/E: 48.76)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.04
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 19.89%
About the Company - Qualitative Analysis
INDUSTRY | ADDRESS | CONTACT |
---|---|---|
Pharmaceuticals | Sun Pharma Advanced Research Centre (SPARC), Tandalja, Vadodra Gujarat 390012 | secretarial@sunpharma.com http://www.sunpharma.com |
Management | |
---|---|
Name | Position Held |
Mr. Dilip S Shanghvi | Chairman & Managing Director |
Mr. Aalok D Shanghvi | Whole Time Director |
Mr. Sudhir V Valia | Non Exe.Non Ind.Director |
Dr. Pawan Goenka | Lead Independent Director |
Mr. Rama Bijapurkar | Independent Director |
Mr. Gautam Doshi | Independent Director |
Mr. Sanjay Asher | Independent Director |
Mr. Rolf Hoffmann | Independent Director |
FAQ
What is the latest fair value of Sun Pharmaceuticals Industries Ltd?
The latest fair value of Sun Pharmaceuticals Industries Ltd is ₹1870.43.
What is the Market Cap of Sun Pharmaceuticals Industries Ltd?
The Market Cap of Sun Pharmaceuticals Industries Ltd is 4,32,276 Cr..
What is the current Stock Price of Sun Pharmaceuticals Industries Ltd as on 08 November 2024?
The current stock price of Sun Pharmaceuticals Industries Ltd as on 08 November 2024 is 1,802.
What is the High / Low of Sun Pharmaceuticals Industries Ltd stocks in FY 2024?
In FY 2024, the High / Low of Sun Pharmaceuticals Industries Ltd stocks is 1,960/1,170.
What is the Stock P/E of Sun Pharmaceuticals Industries Ltd?
The Stock P/E of Sun Pharmaceuticals Industries Ltd is 38.6.
What is the Book Value of Sun Pharmaceuticals Industries Ltd?
The Book Value of Sun Pharmaceuticals Industries Ltd is 288.
What is the Dividend Yield of Sun Pharmaceuticals Industries Ltd?
The Dividend Yield of Sun Pharmaceuticals Industries Ltd is 0.75 %.
What is the ROCE of Sun Pharmaceuticals Industries Ltd?
The ROCE of Sun Pharmaceuticals Industries Ltd is 17.3 %.
What is the ROE of Sun Pharmaceuticals Industries Ltd?
The ROE of Sun Pharmaceuticals Industries Ltd is 16.7 %.
What is the Face Value of Sun Pharmaceuticals Industries Ltd?
The Face Value of Sun Pharmaceuticals Industries Ltd is 1.00.